Replimune Group's (REPL) "Neutral" Rating Reaffirmed at HC Wainwright

Key Points

• Replimune Group's stock received a "neutral" rating from HC Wainwright, reflecting a broader trend of downgrades from various analysts, with price targets significantly lowered by firms like BMO and JPMorgan.
• The company reported a quarterly loss of ($0.95) earnings per share, missing analysts' consensus estimates for the quarter.
• Institutional investors hold 92.53% of Replimune Group's stock, with Tang Capital Management increasing its position by 125% in the last quarter.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "neutral" rating reissued by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports.

Several other equities research analysts have also recently issued reports on the stock. Leerink Partners reiterated a "market perform" rating and set a $3.00 price objective (down previously from $21.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. BMO Capital Markets cut shares of Replimune Group from an "outperform" rating to an "underperform" rating and cut their price objective for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. reissued a "neutral" rating and set a $9.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Piper Sandler lowered shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a research note on Tuesday, July 22nd. Finally, Barclays lowered shares of Replimune Group from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $6.50.

Replimune Group Stock Up 9.0%

NASDAQ:REPL opened at $6.33 on Monday. The firm has a market cap of $494.12 million, a P/E ratio of -1.95 and a beta of 0.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $17.00. The firm has a 50-day simple moving average of $7.02 and a two-hundred day simple moving average of $8.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares of the company's stock, valued at approximately $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC lifted its position in shares of Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after acquiring an additional 1,500,000 shares in the last quarter. MPM Bioimpact LLC purchased a new stake in shares of Replimune Group in the fourth quarter valued at $11,504,000. RTW Investments LP lifted its position in shares of Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after acquiring an additional 931,223 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Replimune Group by 352.5% in the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after acquiring an additional 854,346 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Replimune Group in the first quarter valued at $6,546,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.